Skip to main content

GP2013: A Rituximab Biosimilar


GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. GP2013 has similar physicochemical and pharmacodynamic properties to those of reference rituximab, and the pharmacokinetic biosimilarity of the agents has been shown in patients with RA. GP2013 demonstrated clinical efficacy equivalent to that of reference rituximab in patients with FL, and was generally well tolerated in this population. The tolerability, immunogenicity and safety profiles of GP2013 were similar to those of reference rituximab. The role of reference rituximab in the management of cancers and autoimmune conditions is well established and GP2013 provides an effective biosimilar alternative for patients requiring rituximab therapy.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. Accessed 5 Sept 2017.

  2. Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs. 2013;27(5):495–507.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Da Silva A, Kronthaler U, Koppenburg V, et al. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leuk Lymphoma. 2014;55(7):1609–17.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Smolen JS, Cohen SB, Tony HP, et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2017;76(9):1598–602.

    Article  PubMed  PubMed Central  Google Scholar 

  5. European Medicines Agency. Assessment report: Rixathon (international non-proprietary name: rituximab). 2017. Accessed 5 Sept 2017.

  6. Jurczak W, Moreira I, Kanakasetty GB, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350–61.

    Article  PubMed  Google Scholar 

  7. European Medicines Agency. Summary of product characteristics: Rixathon 100 mg concentrate for solution for infusion, Rixathon 500 mg concentrate for solution for infusion. 2017. Accessed 5 Sept 2017.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations


The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at

Additional information

The manuscript was reviewed by: F. Araujo, Rheumatology and Osteoporosis Unit, Hospital Ortopédico de Sant’Ana, SCML, Parede, Portugal; P. Gascon, Division of Medical Oncology, Hospital Clinic, University of Barcelona, Barcelona, Spain; W. R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A. GP2013: A Rituximab Biosimilar. BioDrugs 31, 465–468 (2017).

Download citation

  • Published:

  • Issue Date:

  • DOI: